Article

Developments in Magnetic Resonance Imaging of Atherosclerosis

Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
Average (ratings)
No ratings
Your rating
Copyright Statement:

The copyright in this work belongs to Radcliffe Medical Media. Only articles clearly marked with the CC BY-NC logo are published with the Creative Commons by Attribution Licence. The CC BY-NC option was not available for Radcliffe journals before 1 January 2019. Articles marked ‘Open Access’ but not marked ‘CC BY-NC’ are made freely accessible at the time of publication but are subject to standard copyright law regarding reproduction and distribution. Permission is required for reuse of this content.

Atherosclerosis is a systemic disease that can silently affect the entire vascular system and often manifests clinically as stroke, myocardial infarction or sudden cardiac death. Despite advances in diagnosis and treatment, the sequelae of atherosclerosis remain the leading cause of death in adult Americans. Traditionally the gold standard for the diagnosis and assessment of atherosclerosis severity has been X-ray angiography which visualizes the reduction in arterial luminal diameter. However, it is now well-known that significant atherosclerotic plaque may be present within the arterial wall long before the lumen is compromised.1 In addition, plaque vulnerability, as determined by plaque composition, may be a better predictor of clinical risk than the severity of arterial stenosis.2 Angiographic modalities, which are blind to the vessel wall, cannot adequately delineate plaque composition and routinely underestimate atherosclerotic burden. Diagnostic techniques capable of imaging the arterial wall and characterizing atherosclerotic plaque provide a more accurate assessment of plaque burden, vulnerability, and possibly patient risk. Thus there is substantial interest in imaging modalities which can look beyond the arterial lumen into the vessel wall, such as high resolution magnetic resonance imaging (MRI).

Magnetic Resonance Imaging of Atherosclerosis

MRI has emerged as a leading non-invasive imaging modality of atherosclerotic disease due to its ability to assess the arterial lumen, plaque burden and plaque components in an accurate and non-invasive manner. MRI has been utilized in the research setting to evaluate atherosclerosis in human carotid, aortic, peripheral and coronary arteries. Several in vitro and in vivo studies have validated the ability of MRI to differentiate the major components of atherosclerotic plaque. In addition, MRI can accurately and reproducibly measure arterial wall dimensions. This has lead to its use as the imaging efficacy end-point in therapeutic trials of plaque regression.

Carotid Atherosclerosis

The carotid artery is an excellent target for MRI of atherosclerosis because of its superficial location, minimal motion, and available tissue pathology from carotid endarterectomy specimens. A substantial amount of work by Yuan and colleagues has validated the ability of MRI to detect and characterize carotid plaque.

They have shown that in vivo MRI can identify the components of a high risk or ‘vulnerable’ plaque such as the lipid rich necrotic core, intraplaque hemorrhage,3 as well as the thickness4 and integrity5 of the fibrous cap. In addition they have demonstrated that a ruptured fibrous cap seen on MRI correlates with a recent history of a transient ischemic attack or stroke.6 Takaya and colleagues have recently shown that patients with asymptomatic moderate carotid stenosis and high risk plaque features had an increased risk of having a subsequent cerebral vascular event.7 It has also been demonstrated that in patients admitted with stroke symptoms, the presence of ruptured hemorrhagic carotid plaque (American Heart Association [AHA] type 6 plaque) strongly correlated with a discharge diagnosis of cerebral ischemic event.8 Thus, a patient could be potentially risk-stratified based on the recognition of high-risk plaque morphology.

Aortic Atherosclerosis

Several investigators have demonstrated the ability to quantify and determine plaque composition in the aorta. Aortic plaque composition and size when visualized with MRI shows a high correlation with transesophageal echocardiography (TEE).9 MRI can measure aortic luminal area as well as plaque area with excellent reproducibility.10 The author’s group has verified the ability of MRI to differentiate fibrous cap, lipid core, and thrombus components of plaque within abdominal aortic aneurysms (AAA) in patients prior to AAA repair (see Figure 1).11

Peripheral Artery Atherosclerosis

Although the peripheral arteries are ideal for vessel wall imaging due to their superficial location, long length, straight course, and lack of motion, they have not been extensively investigated. MRI has been used successfully to define the extent of atherosclerotic plaque and characterize the changes that occur with arterial remodeling following angioplasty of the popliteal artery.12 The feasibility and reproducibility of MRI to assess plaque volume in the superficial femoral artery has been demonstrated13 (see Figure 2). Based on the reproducibility of MRI, sample sizes for clinical trials of atherosclerosis regression could be reduced substantially. These two studies highlight the tremendous potential MRI has to survey the effects of treatment, whether it is invasive or medical, on the progression or regression of atherosclerosis.

Coronary Atherosclerosis

An ultimate goal of MRI is to accurately and rapidly image the coronary artery lumen and vessel wall, and thus provide a more detailed non-invasive alternative to X-ray or computed tomography (CT) angiography. However, the coronary arteries have proven difficult to image due to respiratory and cardiac motion, small size, and tortuosity. Initial attempts aimed at imaging solely the coronary lumen with MRI have met with modest success. In a recent meta-analysis, coronary MR angiography (CMRA) was able to detect nearly 75% of significant proximal stenoses with a specificity of 86% compared with conventional X-ray angiography. Only 80% of the coronary segments were able to be evaluated.14 Thus, at present, CMRA has limited clinical use in diagnosing coronary artery disease (CAD) due to the inability to evaluate distal coronary segments and the high rate of unevaluable segments. Furthermore, it has the same shortcomings as conventional angiographic techniques discussed previously. Investigators have successfully imaged the coronary wall in humans with MRI. Black blood imaging techniques have been used to demonstrate increased coronary wall thickness in patients with CAD (see Figure 3).15 Using three-dimensional (3-D) free-breathing MRI and semi-automated analysis software, coronary vessel wall thickness has been measured with excellent reproducibility.16 Contrast-enhanced coronary plaque imaging is feasible and may aid in differentiating coronary plaque composition.17 However, despite these encouraging studies, it is not yet possible to adequately determine plaque composition, mainly due to limited in-plane spatial resolution of current techniques.

Magnetic Resonance Imaging and Monitoring Atherosclerotic Therapy

Enthusiasm for MRI as the imaging efficacy end-point in therapeutic trials of plaque regression is on the rise due to its ability to image the vessel wall reliably, reproducibly, and in a non-invasive manner. Furthermore, because MRI can measure atherosclerotic plaque with excellent reproducibility, the sample sizes needed to adequately power clinical studies could be dramatically reduced. Excitement over using MRI for this purpose has already spawned several small clinical studies in which MRI has demonstrated significant carotid and aortic plaque regression after treatment with lipid-lowering therapy. Most notably, Corti et al.18,19 used MRI to detect carotid and aortic plaque in 21 asymptomatic hypercholesterolemic patients.

These patients were then placed on lipid-lowering therapy and followed with serial MRI. They found a significant reduction in total vessel area (TVA), a surrogate of atherosclerotic plaque burden, but not luminal area (LA), at one year in both the carotid and aortic plaques. Interestingly, at two years they found a further reduction in TVA and a small but significant increase in LA in both carotid and aortic lesions.

Future Directions

Atherosclerotic plaque imaging with MRI is in a phase of rapid development. Newer pulse sequences are being developed to allow broader coverage in less time.20 Higher field strength magnets, such as 3.0T21 and 7.0T, along with advances in receiver coils, will improve signal/noise ratio (SNR). Undoubtedly, these technological advances will be utilized in vessel wall imaging, especially in the coronary artery where increased spatial resolution and broader coverage is greatly needed. In addition to the developments in MRI hardware and software, the recent developments in contrast agents have improved contrast/noise ratio and thus allow for improved plaque differentiation. Further experience with ultra-small superparamagnetic particles of iron oxide (USPIO)22 in combination with compounds targeting cell adhesion molecules23 will enable visualization of inflamed plaques that are considered vulnerable or at high risk of rupture. Already, USPIOs that are ingested by macrophages have been used to identify macrophage activity, hence inflammation, in in vivo human carotid plaque.24 In addition, there has been excitement over the development of contrast agents that specifically target plaque components such as the lipid core25 or intraplaque thrombus.26 Finally, in the development phase are newer targeted contrast agents aimed at specific cell surface receptors or proteins, which will allow for earlier, more sensitive detection of atherosclerosis. Intravascular MRI (IVMRI) may have a future role in imaging human atherosclerosis. This technique, while invasive, overcomes important limitations of conventional MRI such as SNR and spatial resolution by placing the imaging coil in close proximity to the vessel wall. Plaque imaging has been validated against histopathology in a variety of vascular territories of animals and humans27 with excellent spatial resolution.

Summary

Insights into the pathogenesis of atherosclerosis and technological improvements have moved MRI to the forefront of atherosclerotic imaging. It is developing into an important technique for vessel wall imaging and plaque characterization in the carotid and peripheral arteries as well as in the aorta. While the current spatial resolution hinders the ability of MRI to evaluate the vessel wall of coronary arteries, newer technology is already beginning to overcome this limitation. Clinically, MRI has created a unique opportunity to non-invasively monitor plaque modification over time. This provides an unprecedented platform for efficacy trials of current and novel drugs used in atherosclerosis as well as in interventional therapy. By diagnosing atherosclerosis earlier and by identifying high-risk vulnerable plaque, MRI of atherosclerosis may potentially provide better risk stratification than current angiographic techniques. Ultimately, MRI might be a key modality in the identification of the vulnerable patient in whom focal or systemic intervention could be started to prevent cardiovascular events.

References

  1. Glagov S,Weisenberg E, Zarins CK, et al., Compensatory enlargement of human atherosclerotic coronary arteries, N Engl J Med, 1987;316:1371–5.
    Crossref | PubMed
  2. Virmani R, Kolodgie FD, Burke AP et al., Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions, Arterioscler Thromb Vasc Biol, 2000;20:1262–75.
    Crossref | PubMed
  3. Yuan C, Mitsumori LM, Ferguson MS, et al., In vivo accuracy of multispectral magnetic resonance imaging for identifying lipid-rich necrotic cores and intraplaque hemorrhage in advanced human carotid plaques, Circulation, 2001;104 2051–6.
    Crossref | PubMed
  4. Cai J, Hatsukami TS, Ferguson MS, et al., In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque: comparison of high-resolution, contrast-enhanced magnetic resonance imaging and histology, Circulation, 2005;112:3437–44.
    Crossref | PubMed
  5. Hatsukami TS, Ross R, Polissar NL, et al., Visualization of fibrous cap thickness and rupture in human atherosclerotic carotid plaque in vivo with high-resolution magnetic resonance imaging, Circulation, 2000;102:959–64.
    Crossref | PubMed
  6. Yuan C, Zhang SX, Polissar NL, et al., Identification of fibrous cap rupture with magnetic resonance imaging is highly associated with recent transient ischemic attack or stroke, Circulation, 2002;105:181–5.
    Crossref | PubMed
  7. Takaya N, Yuan C, Chu B, et al., Association between carotid plaque characteristics and subsequent ischemic cerebrovascular events: a prospective assessment with MRI—initial results, Stroke, 2006;37:818–23.
    Crossref | PubMed
  8. Parmar J, Rodgers W, Kramer C, et al., Carotid Plaque MR Imaging During Possible TIA/Ischemic Stroke: A Comprehensive Analysis of Plaque Incidence, Outcomes and Cardiovascular Risk Factors, J Cardiovasc Magn Reson, 2007;9:151–2.
  9. Fayad ZA, Nahar T, Fallon JT, et al., In vivo magnetic resonance evaluation of atherosclerotic plaques in the human thoracic aorta: a comparison with transesophageal echocardiography, Circulation, 2000;101:2503–9.
    Crossref | PubMed
  10. Chan SK, Jaffer FA, Botnar RM, et al., Scan reproducibility of magnetic resonance imaging assessment of aortic atherosclerosis burden, J Cardiovasc Magn Reson, 2001;3:331–8.
    Crossref | PubMed
  11. Kramer CM, Cerilli LA, Hagspiel K, et al., Magnetic resonance imaging identifies the fibrous cap in atherosclerotic abdominal aortic aneurysm, Circulation, 2004;109:1016–21.
    Crossref | PubMed
  12. Coulden RA, Moss H, Graves MJ, et al., High resolution magnetic resonance imaging of atherosclerosis and the response to balloon angioplasty, Heart, 2000;83:188–91.
    Crossref | PubMed
  13. Isbell DC, Meyer CH, Rogers WJ, et al., Reproducibility and reliability of atherosclerotic plaque volume measurements in peripheral arterial disease with magnetic resonance imaging, J Cardiovasc Magn Reson, 2007;1:71–6
    Crossref | PubMed
  14. Danias PG, Roussakis A, Ioannidis JP, Diagnostic performance of coronary magnetic resonance angiography as compared against conventional X-ray angiography: a meta-analysis, J Am Coll Cardiol, 2004;44:1867–76.
    Crossref | PubMed
  15. Kim WY, Stuber M, Bornert P et al., Three-dimensional black-blood cardiac magnetic resonance coronary vessel wall imaging detects positive arterial remodeling in patients with nonsignificant coronary artery disease, Circulation, 2002;106:296–9.
    Crossref | PubMed
  16. Desai MY, Lai S, Barmet C, et al., Reproducibility of 3D freebreathing magnetic resonance coronary vessel wall imaging, Eur Heart J, 2005;26:2320–24.
    Crossref | PubMed
  17. Maintz D, Ozgun M, Hoffmeier A, et al., Selective coronary artery plaque visualization and differentiation by contrast-enhanced inversion prepared MRI, Eur Heart J, 2006;27:1732–6.
    Crossref | PubMed
  18. Corti R, Fayad ZA, Fuster V, et al., Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging, Circulation, 2001;104:249–52.
    Crossref | PubMed
  19. Corti R, Fuster V, Fayad ZA, et al., Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years’ follow-up by high-resolution noninvasive magnetic resonance imaging, Circulation, 2002;106:2884–7.
    Crossref | PubMed
  20. Sakuma H, Ichikawa Y, Chino S, et al., Detection of coronary artery stenosis with whole-heart coronary magnetic resonance angiography, J Am Coll Cardiol, 2006;48:1946–50.
    Crossref | PubMed
  21. Botnar RM, Stuber M, Lamerichs R, et al., Initial experiences with in vivo right coronary artery human MR vessel wall imaging at 3 tesla, J Cardiovasc Magn Reson, 2003;5:589–94.
    Crossref | PubMed
  22. Ruehm SG, Corot C, Vogt P, et al., Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits, Circulation, 2001;103: 415–22.
    Crossref | PubMed
  23. Nahrendorf M, Jaffer FA, Kelly KA, et al., Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis, Circulation, 2006;114:1504–11.
    Crossref | PubMed
  24. Trivedi RA, Mallawarachi C, King-Im JM, et al., Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages, Arterioscler Thromb Vasc Biol, 2006;26:1601–6.
    Crossref | PubMed
  25. Sirol M, Itskovich VV, Mani V, et al., Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging, Circulation, 2004;109:2890–96.
    Crossref | PubMed
  26. Botnar RM, Perez AS, Witte S, et al., In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent, Circulation, 2004;109:2023–9.
    Crossref | PubMed
  27. Rogers WJ, Prichard JW, Hu YL, et al., Characterization of signal properties in atherosclerotic plaque components by intravascular MRI, Arterioscler Thromb Vasc Biol, 2000;20:1824–30.
    Crossref | PubMed